Hikma Pharmaceuticals Plc Director/PDMR Shareholding (4386C)
April 13 2017 - 2:41AM
UK Regulatory
TIDMHIK
RNS Number : 4386C
Hikma Pharmaceuticals Plc
13 April 2017
Hikma Pharmaceuticals PLC - EIP Awards
LONDON, 13 April 2017: Hikma Pharmaceuticals PLC (LSE: HIK)
(NasdaqDubai: HIK) announces that the Remuneration Committee has
made the following conditional awards and nil cost option under the
Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP")
to Persons Discharging Managerial Responsibility ("PDMR") of the
Company.
Awards under the EIP were made on 13 April 2017 at a price of
1,740 pence per Ordinary Share (being the average price for the
30-day period prior to 31 December 2016, in accordance with the EIP
rules) as follows:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Khalid Nabilsi
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Chief Financial Officer
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element B of the 2014
Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest
after 2 years.
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP17.40
volume(s) Volume(s): 26,174
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 13 April 2017
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Khalid Nabilsi
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Chief Financial Officer
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a conditional award to acquire
Shares under Element C of the 2014
Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest
after 3 years.
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP17.40
volume(s) Volume(s): 23,751
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 13 April 2017
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Riad Mishlawi
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status EU Vice President and Global Head
of Injectables
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a nil cost option to acquire
Shares under Element B of the 2014
Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest
after 2 years.
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP17.40
volume(s) Volume(s): 22,241
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 13 April 2017
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Riad Mishlawi
--- --------------------- -----------------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status EU Vice President and Global Head
of Injectables
--- --------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- -----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- -----------------------------------------
b) Nature of The Company granted the named individual
the transaction above a nil cost option to acquire
Shares under Element C of the 2014
Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest
after 3 years.
--- --------------------- -----------------------------------------
c) Price(s) and Price(s): GBP17.40
volume(s) Volume(s): 20,146
--- --------------------- -----------------------------------------
d) Aggregated N/A
information
--- --------------------- -----------------------------------------
e) Date of the 13 April 2017
transaction
--- --------------------- -----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- -----------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHGRGDSRXBBGRX
(END) Dow Jones Newswires
April 13, 2017 03:41 ET (07:41 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024
